Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ampullary Adenocarcinoma × Capecitabine × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 208 Colorectal Neoplasms 172 Rectal Neoplasms 149 Stomach Neoplasms 107 Pancreatic Neoplasms 86 Neoplasm Metastasis 70 Colonic Neoplasms 53 Neoplasms 47 Triple Negative Breast Neoplasms 34 Esophageal Neoplasms 34 Nasopharyngeal Carcinoma 26 Biliary Tract Neoplasms 25 Cholangiocarcinoma 21 Gallbladder Neoplasms 19 Locally Advanced Rectal Cancer 15 Adenocarcinoma 15 Carcinoma, Hepatocellular 14 Colorectal Cancer Metastatic 13 Adenocarcinoma Of Esophagus 12 Gastrointestinal Neoplasms 11 Bile Duct Neoplasms 11 Head and Neck Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Brain Neoplasms 10 Neuroendocrine Tumors 9 Carcinoma, Renal Cell 9 Breast Neoplasms, Male 9 Anus Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 7 Squamous Cell Carcinoma of Head and Neck 7

Interventions

folfirinox 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06068023 2023-10-05

ADAPTA

Fondazione Poliambulanza Istituto Ospedaliero

Ampullary Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡